Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant ...

Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...

Shares of TransMedics (TMDX) are falling after Scorpion Capital revealed its short position on the company Friday. The ...

EST TransMedics (TMDX) down 10% to $65.39 after Scorpion Capital short reportStay Ahead of the Market:Discover outperforming stocks and ...

NDAQ:TMDX) Kehoe Law Firm, P.C. Securities Investigation on Behalf of Investors of TransMedics Group Stock Following Critical Report - NASDAQ: TMDX ...

Scorpion Capital said in a newly-issued short report that in “20 years of shorting, TransMedics (TMDX) is the most extreme and grotesque ...

The report further alleges that TransMedics has been involved in kickbacks, billing fraud, unreported device failures, and ...

TransMedics is a commercial-stage medical technology company working on organ transplant therapy. Check out more about the ...

Despite a Q3 revenue miss and temporary issues, TransMedics' long-term growth prospects remain strong, with plans for ...

Dey, Aiyesha, Jonas Heese, Suraj Srinivasan, and Annelena Lobb. "Ginkgo Bioworks vs. Scorpion Capital: The Debate Over Related-Party Revenues." Harvard Business School Case 123-037, October 2022.

JPMorgan analyst Allen Gong downgraded TransMedics (TMDX) to Neutral from Overweight with a price target of $75, down from $116. The company’s near-term outlook “remains less certain” as ...